These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2006-002744-28 Effektivitätsoptimierte und toxizitätsreduzierte Therapie des metastasierten Kolorektalkarzinoms in der First-line Therapie 2014-04-16 due-trials
Completed, but no date, and reported results 2008-003779-37 Capecitabine and bevacizumab ± vinorelbine as 1st line treatment in HER2/neu-negative metastatic or locally advanced inoperable breast cancer patients bad-data
Completed, but no date, and reported results 2010-021370-11 An open label, single arm trial to characterize patients with metastatic renal cell carcinoma treated with everolimus after failure of the first VEGF-targeted therapy. bad-data
Completed, but no date, and reported results 2011-001138-40 First Line Pazopanib in Poor Risk Patients with Metastatic Renal Cell Carcinoma Einarmige, multizentrische Studie zur Bewertung von Pazopanib als Erstlinientherapie in Hochrisikopatienten mit fortg... bad-data
Reported results 2013-005329-22 An open label, randomized controlled prospective multicenter two arm phase IV trial to determine Patient preference for everolimus in combination with exemestane or capecitabine in combination with b... 2017-09-30 due-trials
Reported results 2015-001603-32 An open-label, multi-center, sINGlE arm clinical study to evaluate treatment efficacy and quality of life in women with hormone-receptor-positive, HER2-negative loco-regionally recurrent or metastati... 2023-02-15 due-trials
Completed, but no date, and reported results 2017-002930-22 A randomized, open-label, multicenter, two-arm, phase III study to evaluate efficacy and quality of life in patients with metastatic hormone receptor-positive HER2-negative breast cancer receiving rib... bad-data